

## CLINICAL PRACTICE

Caren G. Solomon, M.D., *Editor*

## Heparin-Induced Thrombocytopenia

Andreas Greinacher, M.D.

*This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.*

**A 64-year-old woman who is hospitalized with endocarditis and whose condition is clinically stable while she is receiving intravenous antibiotic agents has had a decrease in platelet count from 161,000 per cubic millimeter on day 7 of hospitalization to 60,000 per cubic millimeter on day 9. She has been receiving low-molecular-weight heparin at a dose of 40 mg per day since admission. How should her case be further evaluated and treated?**

## THE CLINICAL PROBLEM

**I**N CONTRAST TO OTHER CONDITIONS CAUSED BY ENHANCED CONSUMPTION, impaired production, or destruction of platelets, which lead to bleeding complications, immune-mediated heparin-induced thrombocytopenia (HIT) does not induce bleeding but rather results in a paradoxical prothrombotic state.<sup>1</sup> This prothrombotic action makes the early recognition of HIT very important. HIT occurs in approximately 1 in 5000 hospitalized patients, with a large variability among patient populations. Patients who receive unfractionated heparin for 7 to 10 days are at the highest risk<sup>2</sup>; incidence rates of 1 to 3% have been reported after cardiac surgery. Thromboembolic complications develop in approximately 50% of patients with confirmed HIT. Venous thrombosis of the large vessels of the lower limbs and pulmonary embolism are the most frequent complications, followed by peripheral arterial thrombosis and then stroke; myocardial infarction is uncommon.<sup>3</sup> Thrombotic complications may also affect other vessels, including the cerebral sinus or splanchnic veins.

The onset of HIT characteristically occurs between 5 and 10 days after heparin is started,<sup>4</sup> both in patients who receive heparin for the first time and in patients with reexposure. However, there are exceptions. For one, major surgery resets the clock (i.e., the window of 5 to 10 days restarts), even if the patient has recently received heparin (e.g., HIT can develop 5 to 10 days after surgery in patients who have been undergoing hemodialysis for a long time).<sup>5</sup> Second, in persons who have received heparin within the previous 90 days (especially,  $\leq 30$  days), there may be persistent circulating anti-platelet factor 4 (PF4)-heparin antibodies, and HIT can start abruptly on reexposure to heparin (rapid-onset HIT); in this case, HIT is sometimes complicated by an anaphylactoid reaction within 30 minutes after a heparin bolus.<sup>6</sup> Otherwise, once the typically transient antibodies have disappeared (median, 50 to 85 days, depending on the assay used),<sup>4</sup> the regeneration of antibodies requires at least 5 days (no earlier anamnestic response).<sup>7,8</sup> In some patients, HIT develops or worsens after heparin has been discontinued (delayed-onset HIT). These patients can present with thrombosis up to 3 weeks after the

From Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany. Address reprint requests to Dr. Greinacher at Institut für Immunologie und Transfusionsmedizin, Sauerbruchstr., 17475 Greifswald, Germany, or at greinach@uni-greifswald.de.

N Engl J Med 2015;373:252-61.

DOI: 10.1056/NEJMc1411910

Copyright © 2015 Massachusetts Medical Society.



An audio version  
of this article  
is available at  
[NEJM.org](http://NEJM.org)

## KEY CLINICAL POINTS

**HEPARIN-INDUCED THROMBOCYTOPENIA**

- Heparin-induced thrombocytopenia (HIT) is characterized by a decrease in the platelet count of more than 50% from the highest platelet count value after the start of heparin, an onset 5 to 10 days after the start of heparin, hypercoagulability, and the presence of heparin-dependent, platelet-activating IgG antibodies.
- Use of a scoring system that takes into account the timing and magnitude of the platelet count fall, new thrombosis, and the likelihood of other reasons for thrombocytopenia is helpful in assessing the pretest probability of HIT.
- Delayed-onset HIT develops after the cessation of heparin, and spontaneous or autoimmune HIT develops in the absence of heparin exposure.
- Platelet factor 4–heparin antibody tests should be ordered only if clinical features reasonably suggest HIT. These tests have a high negative predictive value but a low positive predictive value.
- Treatment of acute HIT requires the cessation of heparin and the initiation of therapeutic-dose anticoagulation with an alternative agent (argatroban, danaparoid, fondaparinux, or bivalirudin).
- Warfarin should be avoided in patients with acute HIT.

start of heparin exposure.<sup>9</sup> Note that in some cases, a single heparin bolus is sufficient to induce the syndrome, so the start of heparin is the only fixed time point.

A rare but often catastrophic form of HIT is spontaneous<sup>10,11</sup> or autoimmune HIT, which develops in the absence of heparin exposure, most often after major surgery (especially knee replacement) or recent infection. In contrast to typical HIT, in which the platelet count increases within 2 to 5 days after the start of an alternative anticoagulant, autoimmune HIT may persist for weeks.<sup>10</sup>

## PATHOGENESIS

HIT is induced by IgG antibodies recognizing neoepitopes on the positively charged chemokine PF4 within PF4–polyanion complexes (Fig. 1).<sup>12-14</sup> The resulting immune complexes cross-link Fcγ receptors on platelets (Fcγ RIIa)<sup>15</sup> and monocytes (Fcγ RI),<sup>16-18</sup> thus activating them. Further enhanced by the alteration of endothelial cells,<sup>19</sup> the activation of platelets and monocytes increases thrombin generation. Increased thrombin, not thrombocytopenia, causes the clinical problems.

In addition to binding heparin, PF4 binds other polyanions, such as nucleic acids<sup>20</sup> and lipopolysaccharides on bacteria.<sup>21</sup> This phenomenon may explain cases of spontaneous HIT after major surgery (causing DNA, RNA, or glycosaminoglycan release) or bacterial infection. An interesting concept<sup>22</sup> is that conformationally changed<sup>23</sup> PF4 in complex with nonheparin poly-

anions (e.g., on the bacterial surface) induces primary immunization. These PF4–polyanion complexes serve as a danger signal and result in the rapid generation of IgG antibodies, which facilitate opsonization and phagocytosis of PF4-coated bacteria, even against PF4-labeled pathogens that the immune system has not encountered before. This mechanism, however, results in HIT when it is misdirected<sup>22</sup> during heparin treatment as a secondary immune reaction toward platelets coated with PF4–heparin complexes, which results in early production (between day 5 and day 14) of high-titer IgG antibodies. Anti-PF4–heparin antibodies are produced by B cells (probably marginal-zone B cells),<sup>24</sup> which can mediate a transient antibody response.


## STRATEGIES AND EVIDENCE

**RISK OF HIT**

The risk of HIT depends on the type of heparin and the patient population. The incidence is up to 10 times as high among patients receiving unfractionated heparin as it is among those receiving low-molecular-weight heparin,<sup>25</sup> and HIT occurs more frequently among patients who have had major surgery than among those who have had minor surgery<sup>26</sup> or are receiving medical therapy.<sup>27</sup> HIT is rare in obstetrical patients, although in contexts other than pregnancy, women are at slightly higher risk than men.<sup>27</sup>

**DIAGNOSIS**

The diagnosis of HIT is based on a decrease in the platelet count of more than 50% or throm-




**Figure 1. Pathogenesis of Heparin-Induced Thrombocytopenia.**

The adverse drug effect known as heparin-induced thrombocytopenia (HIT) shows many similarities to a bacterial host defense mechanism. Platelet factor 4 (PF4) that is released from platelet  $\alpha$ -granules binds to polyanions such as heparin or polyanions on the surface of bacteria and undergoes a conformational change. This results in immunogenic PF4-polyanion (heparin) or PF4-polyanion (bacteria) complexes. After activation, B lymphocytes (probably marginal-zone B cells) generate anti-PF4-polyanion IgG. These antibodies can bind to different PF4-coated bacteria and opsonize them. However, these antibodies also bind to PF4-heparin complexes, forming immunocomplexes. The Fc parts of the IgG bind to platelet Fc $\gamma$ RIIa receptors, resulting in Fc $\gamma$ -receptor clustering and consequent strong platelet activation and aggregation. This intravascular platelet consumption causes a decrease in the platelet count and the production of platelet-derived microparticles that accelerate thrombin generation. In addition, HIT antibodies activate monocytes (by means of the Fc $\gamma$ RI) and (directly or indirectly) endothelial cells, inducing additional tissue-factor expression. The resulting increase in thrombin generation leads to an increased risk of thrombosis among patients with HIT, providing a rationale for treatment that reduces thrombin generation.

basis beginning 5 to 10 days after the start of heparin, in association with the appearance of platelet-activating HIT antibodies, as shown by means of a functional assay or inferred by means of a strong positive immunoassay. The fall in platelet count in HIT occurs rapidly (over a period of 1 to 3 days) and is assessed relative to the highest platelet count after the start of heparin. The typical nadir is 40,000 to 80,000 platelets per cubic millimeter, but the count may remain in the normal range (e.g., a decline from 500,000 to 200,000 per cubic millimeter). In less than 10% of patients, the decrease in platelet count is less pronounced (30 to 50% of the highest preceding value). Rarely, the platelet count may fall below 20,000 per cubic millimeter, especially when HIT is associated with other causes of thrombocytopenia, such as consumptive coagulopathy.<sup>1</sup>

Although monitoring of platelet counts facilitates the recognition of HIT, it is difficult to justify in many patients, especially outpatients. Monitoring should be considered when the risk of HIT is relatively high (>1%), such as among patients who have undergone cardiac surgery and those receiving unfractionated heparin after major surgery<sup>28</sup> (other than heparin received for intraoperative flushes or catheter-related flushes). After major surgery, patients typically have a reactive platelet count increase that exceeds the baseline value (i.e., the value before the receipt of heparin) after the first postoperative week. Given the typical time window of HIT,<sup>4</sup> platelet count monitoring on days 5, 7, and 9 allows for the early recognition of HIT in the majority of patients.<sup>29</sup> Even if HIT manifests thereafter, the platelet count on day 9 is close to the peak post-surgery platelet count. Monitoring platelet counts on these days facilitates later recognition of a fall in the platelet count of more than 50%, which can be missed when only the lower pre-surgery baseline value is considered. Even with platelet count monitoring, however, the first thrombotic complication may not be preventable, because in approximately 20% of patients it occurs shortly before, or concomitant with, the platelet count decrease (Fig. 2).<sup>30</sup>

Scoring systems can be helpful in estimating the probability of HIT.<sup>31,32</sup> A widely used scoring system is the 4T score,<sup>31</sup> which evaluates four indicators: the relative platelet count fall, the timing of the onset of the platelet count fall, the presence or absence of thrombosis, and the like-



**Figure 2. Timing of HIT and Rationale for Platelet Count Monitoring at Various Time Points.**

Guidelines from the American College of Chest Physicians (ACCP)<sup>28</sup> recommend platelet count monitoring in patients with a risk of HIT that is higher than 1% (e.g., patients undergoing cardiac surgery, those receiving unfractionated heparin at either a prophylactic or therapeutic dose, and those with cancer). The shaded curve shows the median (black line)  $\pm 2$  SD of the platelet count in 452 patients who underwent trauma surgery.<sup>26</sup> After major surgery, the platelet count (black line) reaches its nadir between day 2 and day 4, followed by a reactive increase that exceeds the baseline value. Because HIT typically manifests between day 5 and day 10, platelet count monitoring before day 1 and on days 5, 7, and 9 (purple arrows) is appropriate to identify the majority of patients with HIT. Comparing the platelet count at the onset of a HIT-related new thrombosis with the presurgery baseline platelet count will often not reveal the 50% decrease without documented preceding platelet counts. This situation is exemplified by an individual patient's platelet count course (blue line). At the time that HIT-related thrombosis became evident, comparison of the actual platelet count (lower dashed line) with the presurgery platelet count (upper dashed line) shows only a 30% decrease (right red arrow), whereas comparison with the platelet count peak at days 6 and 7 shows the fall in the platelet count of more than 50% (left red arrow), which is indicative of HIT. Patients who are receiving medical therapy do not have this reactive increase in the platelet count, and it is sufficient to compare the platelet count at the time of clinical suspicion of HIT with the baseline platelet count (before the administration of heparin). LMWH denotes low-molecular-weight heparin.

likelihood of another cause, with scores on the individual components ranging from 0 to 2 and higher scores indicating a higher likelihood of HIT. A total score of less than 4 points has a very high negative predictive value (97 to 99%) (Table 1),<sup>31,33</sup> whereas the positive predictive value is low (10 to 20% for an intermediate score [4 or 5 points] and 40 to 80% for a high score [6

**Table 1. 4T Scoring System for Evaluating the Pretest Probability of Heparin-Induced Thrombocytopenia.\***

Variable	Score		
	2	1	0
Acute thrombocytopenia	Platelet count decrease of >50% and nadir $\geq 20,000/\text{mm}^3$	Platelet count decrease of 30–50% or nadir 10,000–19,000/ $\text{mm}^3$	Platelet count decrease of <30% or nadir $\leq 10,000/\text{mm}^3$
Timing of onset	Day 5–10, or day 1 if recent heparin exposure	>Day 10 or unclear exposure	$\leq$ Day 4 with no recent heparin exposure
Thrombosis	New thrombosis or anaphylactoid reaction after heparin bolus	Progressive or recurrent thrombosis	None
Other cause of thrombocytopenia	None	Possible	Definite
<b>Total score</b>	6–8, indicating high score	4 or 5, indicating intermediate score	0–3, indicating low score

\* Adapted from Lo et al.<sup>31</sup> A low 4T score (0 to 3 points) has a high negative predictive value. The day that heparin was started is considered as day 0. The onset of heparin-induced thrombocytopenia (HIT) is defined as the day that the platelet count begins to decrease. Patients in whom the score is difficult to apply, owing to missing platelet count values or coexisting conditions causing thrombocytopenia, and those with an intermediate or high score require further evaluation. This score can be included on ordering forms for HIT laboratory testing (e.g., [www2.medin.uni-greifswald.de/transfus/fileadmin/user\\_upload/doku\\_thrombo\\_gerinnung/platelet\\_lab\\_request\\_form.pdf](http://www2.medin.uni-greifswald.de/transfus/fileadmin/user_upload/doku_thrombo_gerinnung/platelet_lab_request_form.pdf)).

to 8 points)).<sup>32</sup> A falsely low score may result from missing platelet count values or coexisting conditions that may also underlie thrombocytopenia. For patients with missing values or coexisting conditions and for those whose score is intermediate or high, laboratory tests are needed to rule out HIT.

#### ADDITIONAL LABORATORY TESTING

Anti-PF4-heparin enzyme immunoassays have an excellent negative predictive value (98 to 99%)<sup>34</sup> but a low positive predictive value, owing to the detection of clinically insignificant anti-PF4-heparin antibodies. In systematic serosurveillance studies, clinically evident HIT developed in only a minority (2 to 15%) of heparin-treated patients who had anti-PF4-heparin antibodies detected by means of enzyme immunoassay.<sup>35,36</sup> In patients with thrombocytopenia who have a negative test, repeat testing is generally not indicated in the absence of a new decrease in the platelet count or a thrombotic event. Anti-PF4-heparin antibodies are always present before the platelet count begins to decline,<sup>37</sup> and seroconversion after an initially negative test for anti-PF4-heparin antibodies nearly always detects coincidental, clinically irrelevant antibodies. Overdiagnosis and associ-

ated overtreatment of HIT are probably more common than underrecognition, given the high frequency of thrombocytopenia among early postoperative and critically ill patients and the low specificity of the assays.

Several strategies can be used to increase the specificity of PF4-heparin enzyme immunoassays. One strategy is the restriction of the assay to IgG antibodies, because only IgG activates platelets and monocytes by means of Fc $\gamma$  receptors, yet some commercial assays detect combined IgG, IgA, and IgM. Also, the magnitude of anti-PF4-heparin reactivity on enzyme immunoassay should be considered, because greater reactivity correlates with a greater likelihood of HIT; an optical density of less than 1.0 on enzyme immunoassay is rarely associated with clinically relevant anti-PF4-heparin antibodies.<sup>38</sup> However, optical-density values are arbitrary units and may vary among laboratories.<sup>39</sup> Inhibition of the enzyme immunoassay by high concentrations of heparin also increases specificity, but the most relevant, very strongly reacting antibodies may not be inhibited.<sup>34</sup>

Diagnostic accuracy for HIT is improved with the use of both an anti-PF4-heparin enzyme immunoassay and a functional test (e.g., a platelet-activation assay). In particular, platelet-

activation assays with the use of washed platelets<sup>34</sup> (e.g., serotonin-release assay and heparin-induced platelet-activation test, both with the use of high heparin inhibition) are much more specific than enzyme immunoassays for clinically relevant antibodies and also detect the rare antibodies with other specificities.<sup>34</sup> A negative functional assay essentially rules out HIT. These assays are restricted to specialized laboratories and are usually applied as second-line tests in the diagnostic workup of HIT.

HIT assays should not be used to screen asymptomatic patients and should be interpreted only in the context of the pretest probability of HIT.<sup>33,34</sup> A low or intermediate 4T score together with a negative antigen test rules out HIT, whereas an intermediate or high score together with a positive functional assay makes HIT very likely (Fig. 3).

In a subgroup of patients, anti-PF4-heparin antibodies show very high optical densities (>2.0) and strongly activate platelets even in the absence of heparin. First recognized in delayed-onset HIT,<sup>9</sup> these autoreactive antibodies mediate spontaneous HIT. They may also be transiently present during the first 5 to 7 days in typical HIT, without affecting treatment.<sup>40,41</sup>

In patients with strongly suspected or confirmed HIT, duplex ultrasonography can rule out subclinical deep-vein thrombosis, which may affect the duration of treatment.<sup>1</sup> In patients with HIT who have abdominal pain or hypotension, bilateral adrenal hemorrhage associated with adrenal-vein thrombosis should be considered; severe headache should prompt the consideration of cavernous sinus thrombosis.


#### TREATMENT

Key interventions in patients with highly suspected or confirmed acute HIT are the prompt cessation of heparin (if still being administered) and the initiation of an alternative anticoagulant at a therapeutic dose. Prophylactic-dose anticoagulation is insufficient<sup>42</sup> to compensate for massive thrombin generation, even if the patient has no apparent thrombosis. Vitamin K antagonists (e.g., warfarin and phenprocoumon) should not be given until HIT has abated (e.g., the platelet count has increased to >150,000 per cubic millimeter at a stable plateau for 2 consecutive days), because they increase the risk of venous limb gangrene and limb loss by decreasing the

level of protein C. When vitamin K antagonists are initiated, overlap with an alternative anticoagulant is needed.<sup>29</sup>

Two drugs are approved for the treatment of HIT — the direct thrombin inhibitor argatroban (in the United States, Canada, the European Union, and Australia) and the antithrombin-dependent factor Xa inhibitor danaparoid (in Canada, the European Union, and Australia).<sup>29</sup> An analysis of prospective cohorts showed a reduced risk of the composite outcome of new thrombosis, death due to thrombosis, or amputation related to thrombosis in patients treated with argatroban, as compared with historical controls (hazard ratio for the composite outcome among patients with HIT without thrombosis, 0.33; 95% confidence interval [CI], 0.20 to 0.54; hazard ratio for the composite outcome among patients with HIT with thrombosis, 0.30; 95% CI, 0.25 to 0.62).<sup>43</sup> An analysis of outcomes with danaparoid<sup>29</sup> that was provided on a compassionate-use basis showed a rate of treatment success (platelet count recovery without new thrombosis and absence of major adverse events requiring drug cessation) that was higher than 90%.<sup>44</sup> In a small, open-label, randomized trial comparing danaparoid with dextran 70 for the treatment of HIT with thrombosis, the rates of recovery from thromboembolism were significantly higher with danaparoid.<sup>45</sup> Fondaparinux and bivalirudin are also used in this context, although they have not been approved by the Food and Drug Administration for this indication. Case series have shown good outcomes in patients with HIT treated with fondaparinux<sup>29,46</sup> or bivalirudin.<sup>28,47</sup>

Argatroban is frequently used in critically ill patients. It has a relatively short half-life, which is independent of renal function, but it requires intravenous administration. Because argatroban affects the international normalized ratio, the transition to warfarin has to follow a special protocol.<sup>28</sup> An underrecognized issue is that the activated partial-thromboplastin time may be falsely high when argatroban is given to patients who have additional coagulopathies (e.g., consumptive coagulopathy or impaired liver function) or to patients who have received pretreatment with warfarin. This situation may lead to underdosing of argatroban, with the risk of progressive microvascular thrombosis and ischemic limb loss. This limitation may be overcome



**Figure 3. Diagnosis of HIT.**

The flowchart provides a guide to decision making regarding a patient who is suspected to have HIT. Antigen assays for PF4–heparin antibodies are widely available, whereas functional assays with the use of washed platelets, such as the serotonin-release assay (SRA) or the heparin-induced platelet-activation (HIPA) test, are restricted to specialized laboratories. In centers where a functional assay is unavailable or cannot be obtained promptly, other options include the use of high reactivity of the antigen test (e.g., optical density [OD], >1.0) as a surrogate marker for clinically relevant antibodies or incorporating the 4T score in interpretation (dashed lines), although the overdiagnosis of HIT remains possible. The 4T scoring system evaluates four indicators (the relative platelet count fall, the timing of the onset of the platelet count fall, the presence or absence of thrombosis, and the likelihood of another cause), with scores on the individual components ranging from 0 to 2 and higher scores indicating a greater likelihood of HIT. In the case of a high 4T score and a negative result on the PF4–heparin IgG antibody immunoassay, consider that laboratory error may be a cause of a false negative result. Even if short-term treatment decisions are made without confirmation of the presence of platelet-activating, heparin-dependent antibodies, efforts should be made to rule out or confirm the presence of these antibodies to guide the future treatment of the patient.

by the use of an ecarin-based clotting assay (which has limited availability) or the plasma-diluted thrombin time assay (for which an in-house standard for argatroban is required).

Danaparoid can be administered intravenously or subcutaneously, whereas fondaparinux is given only subcutaneously. These two drugs can be reliably monitored by anti-factor Xa assays, but they have long half-lives and in patients with renal insufficiency, a dose adjustment will be necessary. Subcutaneous injection makes these drugs easier than argatroban to use outside the intensive care unit. In addition, danaparoid interferes with the immune mechanism of HIT by disrupting PF4-heparin complexes.<sup>48</sup> Exacerbations of HIT have been reported infrequently with the use of either danaparoid or fondaparinux. Although most cases of exacerbations are attributable to autoimmune HIT antibodies and are independent of these drugs, a small percentage of patients have true *in vivo* and *in vitro* cross-reactivity. If manifestations of HIT worsen despite sufficient levels of anti-factor Xa activity in patients taking danaparoid or fondaparinux, treatment should be switched (e.g., to argatroban).

Prophylactic platelet transfusions should be avoided in patients with HIT. The risk of bleeding is very low, and such transfusions can increase the risk of thrombosis.<sup>49</sup>

---

#### AREAS OF UNCERTAINTY

---

Whereas *in vitro* data suggest that dabigatran, rivaroxaban, and apixaban might also be used to treat patients with HIT,<sup>50</sup> more data are needed before these drugs can be recommended in the context of acute HIT. A concern is whether trough levels are sufficient to prevent thrombin generation by strongly reactive anti-PF4-heparin antibodies.

Patients who have HIT with thrombosis require therapeutic-dose anticoagulation for at least 3 months. However, in patients who have HIT without thrombosis, the duration of therapeutic-dose anticoagulation after the platelet count has reached a stable plateau (ideally >150,000 per cubic millimeter)<sup>28</sup> is unresolved.

High-dose intravenous immune globulin G (e.g., at a dose of 2 g per kilogram of body weight over a 2-day period) interferes with HIT by blocking platelet Fcγ receptors. Limited data suggest that this drug may be an option (along

with anticoagulation) in patients at high risk for thrombosis and bleeding (e.g., those who are pregnant or have sinus-vein thrombosis complicating HIT) or in patients who have autoimmune HIT.<sup>51</sup>

PF4 forms complexes with negatively charged nucleic acids and aptamers,<sup>20</sup> which cross-react with anti-PF4-heparin antibodies. Aptamers and other nucleic acid-based drugs are entering clinical application, and it is unclear whether they can induce HIT.

In patients with a history of HIT who require cardiac surgery, postponing surgery until platelet-activating anti-PF4-heparin antibodies disappear and then using heparin intraoperatively is a safe approach.<sup>8,28,52</sup> Another option in urgent situations is the removal of platelet-activating anti-PF4-heparin antibodies by plasmapheresis, as described in anecdotal reports.<sup>53</sup> Otherwise, bivalirudin is a compatible anticoagulant for cardiac surgery if platelet-activating anti-PF4-heparin antibodies are present. However, its use requires special approaches to avoiding stagnation of blood (which results in degradation of bivalirudin).<sup>28</sup>

---

#### GUIDELINES

---

The guidelines of the American College of Chest Physicians (ACCP)<sup>28</sup> and national European guidelines<sup>54-56</sup> address HIT. In the absence of data from randomized trials, most recommendations are supported by low-grade evidence. All these guidelines recommend the use of a scoring system to determine the probability of HIT before testing is performed and note the need for therapeutic-dose anticoagulation in cases of acute HIT. Guidelines differ with each other regarding specific recommendations about which patients should undergo routine platelet count monitoring and the frequency of monitoring. The ACCP guidelines recommend assessing patients at high risk (>1%) for HIT every 2 to 3 days between day 4 and day 14.<sup>28</sup>

---

#### CONCLUSIONS AND RECOMMENDATIONS

---

The patient described in the vignette had a marked decrease in the platelet count after several days of therapy with low-molecular-weight heparin, which raises concern about HIT. Calculation of the 4T score is recommended to determine

her risk of HIT. Her score of 5 points (decrease in platelet count, 2; timing, 2; thrombosis, 0; and likelihood of other reasons, 1, since her endocarditis is stable and the platelet count is too high for antibiotic-induced immune thrombocytopenia) places her at intermediate risk. Although routine screening for PF4-heparin antibodies is strongly discouraged, patients at intermediate or high risk should undergo this testing. A positive anti-PF4-heparin IgG enzyme immunoassay is necessary for the diagnosis of HIT but is nonspecific. A strongly positive test (optical density, >1.5) or positive platelet-activation assay would strongly support the diagnosis of HIT. Treatment involves the prompt cessation of heparin and the initiation

of an alternative anticoagulant (argatroban or danaparoid, both of which are approved for this indication, or fondaparinux or bivalirudin, with use of these agents supported by case series).

Dr. Greinacher reports receiving fees for serving on an advisory board from Instrumentation Laboratory; consulting fees from Bayer HealthCare, Macopharma, Merck Sharp & Dohme, and W.L. Gore and Associates; travel support from Boehringer Ingelheim; fees for the planning of and participation in a Continuing Medical Education program from Bristol-Myers Squibb; grant support from Macopharma; and institutional fees to his university from Boehringer Ingelheim. He also reports an agreement in development with BioMarin Nederland and Nanjing King-friend Biochemical Pharmaceutical, which will provide institutional but no personal fees. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

#### REFERENCES

- Greinacher A, Warkentin TE, Chong BH. Heparin-induced thrombocytopenia. In: Michelson AD, ed. Platelets. 3rd ed. Oxford, United Kingdom: Elsevier's Science and Technology, 2012:851-82.
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med* 1995;332:1330-5.
- Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. *Am J Med* 1996;101:502-7.
- Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med* 2001;344:1286-92.
- Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. *Nephrol Dial Transplant* 1997;12:2750-5.
- Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. *Expert Opin Drug Saf* 2009;8:129-44.
- Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. *N Engl J Med* 2000;343:515.
- Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. *Blood* 2014;123:2485-93.
- Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. *Ann Intern Med* 2001;135:502-6.
- Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. *Blood* 2014;123:3651-4.
- Greinacher A. Me or not me? The danger of spontaneity. *Blood* 2014;123:3536-8.
- Brandt S, Krauel K, Gottschalk KE, et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. *Thromb Haemost* 2014;112:53-64.
- Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. *Blood* 1998;92:3250-9.
- Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. *Blood* 2002;99:1230-6.
- Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. *Blood* 1988;72:925-30.
- Gruel Y, Pouplard C, Lasne D, Magdeleine-Beuzelin C, Charroing C, Watier H. The homozygous FgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. *Blood* 2004;104:2791-3.
- Kasthuri RS, Glover SL, Jonas W, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. *Blood* 2012;119:5285-93.
- Rauova L, Hirsch JD, Greene TK, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. *Blood* 2010;116:5021-31.
- Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. *N Engl J Med* 1987;316:581-9.
- Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. *Blood* 2013;122:272-81.
- Krauel K, Weber C, Brandt S, et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. *Blood* 2012;120:3345-52.
- Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. *Blood* 2011;117:1370-8.
- Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. *Blood* 2014;124:2442-9.
- Zheng Y, Yu M, Podd A, et al. Critical role for mouse marginal zone B cells in PF4/heparin antibody production. *Blood* 2013;121:3484-92.
- Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood* 2005;106:2710-5.
- Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. *Blood* 2010;115:1797-803.
- Greinacher A, Warkentin TE. Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. *Expert Rev Hematol* 2008;1:75-85.
- Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;141:2 Suppl:e495S-e530S.
- Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133:6 Suppl:340S-380S.

30. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. *Thromb Haemost* 2005;94:132-5.
31. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. *J Thromb Haemost* 2006;4:759-65.
32. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. *J Thromb Haemost* 2010;8:2642-50.
33. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. *Blood* 2012;120:4160-7.
34. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. *Heparin-induced thrombocytopenia*. 5th ed. New York: Informa Healthcare, 2013:272-314.
35. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. *Blood* 2000;96:1703-8.
36. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. *Br J Haematol* 2005;128:837-41.
37. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. *Blood* 2009;113:4963-9.
38. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. *J Thromb Haemost* 2008;6:1304-12.
39. Greinacher A, Ittermann T, Bagemühl J, et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. *J Thromb Haemost* 2010;8:2025-31.
40. Socher I, Kroll H, Jorjks S, Santos S, Sachs UJ. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence. *J Thromb Haemost* 2008;6:197-200.
41. Prechel MM, McDonald MK, Jeske WP, Messmore HL, Walenga JM. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. *J Thromb Haemost* 2005;3:2168-75.
42. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. *Thromb Haemost* 2001;85:950-7.
43. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. *Chest* 2006;129:1407-16.
44. Chong BH, Magnani H. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. *Heparin-induced thrombocytopenia*. 5th ed. New York: Informa Healthcare, 2013:466-88.
45. Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. *Thromb Haemost* 2001;86:1170-5.
46. Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. *Blood* 2015;125:924-9.
47. Bartholomew JR, Prats J. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. *Heparin-induced thrombocytopenia*. 5th ed. New York: Informa Healthcare, 2013:429-65.
48. Krauel K, Füll B, Warkentin TE, et al. Heparin-induced thrombocytopenia — therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. *J Thromb Haemost* 2008;6:2160-7.
49. Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. *Blood* 2015;125:1470-6.
50. Krauel K, Hackbarth C, Füll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. *Blood* 2012;119:1248-55.
51. Tivito A, Bakchoul T, Rowe JM, Greinacher A, Ganzel C. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. *Am J Hematol* 2015;90:675-8.
52. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. *Blood* 2008;112:4024-7.
53. Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. *Blood* 2015;125:195-8.
54. Watson H, Davidson S, Keeling D; Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. *Br J Haematol* 2012;159:528-40.
55. The Association of the Scientific Medical Societies of Germany. German guidelines for thrombosis prophylaxis (<http://www.awmf.org/leitlinien/detail/ll/003-001.html>).
56. The Association of the Scientific Medical Societies of Germany. German guidelines for thrombosis therapy (<http://www.awmf.org/leitlinien/detail/ll/065-002.html>).

Copyright © 2015 Massachusetts Medical Society.

#### IMAGES IN CLINICAL MEDICINE

The *Journal* welcomes consideration of new submissions for Images in Clinical Medicine. Instructions for authors and procedures for submissions can be found on the *Journal's* website at [NEJM.org](http://NEJM.org). At the discretion of the editor, images that are accepted for publication may appear in the print version of the *Journal*, the electronic version, or both.